PE 22-28 (PE 22-28 (Spadin-Derived TREK-1 Peptide))
A synthetic peptide derived from spadin that blocks the TREK-1 potassium channel, researched as a fast-acting antidepressant and neuroplasticity agent. Biohackers track it for mood, neurogenesis, and stroke-recovery research; it remains preclinical.
How it works
Selectively blocks the TREK-1 background potassium channel. TREK-1 inhibition enhances serotonergic signaling and rapidly increases synaptogenesis and neurogenesis, producing antidepressant-like effects faster than SSRIs in animal models.
Key facts
- Molecular weight: ~ (7-residue peptide)
- Half-life: Short (peptide; improved vs spadin)
- Bioavailability: Intranasal or injection (research)
- Storage: Lyophilized: -20°C. Reconstituted: 2-8°C.
Dosing overview
- Typical dose: Not established for humans
- Frequency: Research only
- Duration: Research only
- Route: Intranasal or injection (research)
Protocol notes
- No validated human dosing exists; all use is experimental and unapproved.
- Animal studies used weight-based dosing showing rapid antidepressant and neurogenic effects.
- Included for educational completeness.
Reported benefits
- Rapid antidepressant effects (preclinical)
- Promotes neurogenesis and synaptogenesis
- TREK-1 channel blockade
- Neuroplasticity research interest
Possible side effects
- Unknown human safety
- No approved human use
- Unproven efficacy in humans
Research
- PE 22-28 and TREK-1 antidepressant effects (2017): The spadin analog PE 22-28 blocked TREK-1 and produced rapid antidepressant and neurogenic effects in rodent models.
Compare PE 22-28
Research and educational reference only. Not medical advice.